Last Updated on February 27, 2021 by The Health Master
Zydus Cadila has received final approval from the USFDA to market Nortriptyline Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg and 75 mg (US RLD: Pamelor Capsules).
This medication is used to treat mental / mood problems such as depression.
It may help improve mood and feelings of well-being, relieve anxiety and tension, and increase one’s energy level.
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 313 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Also read:
Granules gets USFDA nod for Acetaminophen, Aspirin and Caffeine tablets
Strides gets USFDA Yes for Ibuprofen OTC Oral Suspension
Sun Pharma to launch entire range of Epilepsy treatment drug in India
Dr Reddy’s launch Lansoprazole DR orally disintegrating tablets
Unichem gets USFDA approval for Apremilast Tablets
Lupin gets USFDA nod to market generic Droxidopa capsules
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
Go to main website, click here
Follow and connect with us on Facebook and Linkedin
Subscribe for daily free updates, click here
For daily free updates on WhatsApp, click here
